Clinical pharmacology and leonhard’s classification of endogenous psychoses

Psychopathology

Volumn 23, Issue 4-6, 1990, Pages 331-338

  Ban, Thomas A ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXAPINE; ANTIDEPRESSANT AGENT; LITHIUM; NEUROLEPTIC AGENT;

BIOLOGY; CLASSIFICATION; CONFERENCE PAPER; DEPRESSION; ENDOGENOUS PSYCHOSIS; HUMAN; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMAN; LITHIUM; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0025609540     PISSN: 02544962     EISSN: None     Source Type: Journal    
DOI: 10.1159/000284677     Document Type: Article

References (36)

1. Leonhard K: Aufteilung der endogenen Psychosen. Berlin, Akademie-Verlag, 1957.
2. Wernicke C: Grundriss der Psychiatrie. Leipzig, Thieme. 1900.
3. Carpenter, WT, McGlashan, TH, Strauss, JS: The treatment of acute schizophrenia without drugs: An investigation of some current assumptions. Am J Psychiatry 1977;134:14-20.
4. Davis JM: Maintenance therapy in psychiatry. Schizophrenia. Am J Psychiatry 1975; 132:1237-1245.
5. Hollister LE, Kim DY: Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1466-1468.
6. Rimon R. Averbuch H. Rozick P, et al: Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology 1981;73:197-199.
7. Ban TA, Guy W, Wilson WH: Description and distribution of the subtypes of schizophrenia based on Leonhard’s classification. Psychiatr Dev 1984;3:179-199.
8. Angrist B, Rotrosen J, Gershon S: Responses to apomorphine. amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacology 1980;67:31-38.
9. Ban TA: Prolegomenon to the clinical prerequisite: Psychopharmacology and the classification of mental disorders. Prog Neuropsychopharmacol Biol Psychiatry 1987.11:527-580.
10. Crow TJ: Molecular pathology of schizophrenia: More than one disease process. Br Med J 1980; 280:66-68.
11. Crow TJ: Positive and negative schizophrenia and the role of dopamine. Br J Psychiatry 1981; 139: 251-254.
12. Goldberg SC: Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 1985;11:453-456.
13. Bowers, MB, Swigar, ME, Jetlov PI, et al: Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 1984;6:248-251.
14. Gelder M, Kolakowska T: Variability of response to neuroleptics in schizophrenia: Clinical, pharmacologic, and neuroendocrine correlates. Compr Psychiatry 1979;20:397-408.
15. Astrup C: The effects of ataraxic drugs on schizophrenic subgroups related to experimental findings. Acta Psychiatr Scand 1959;34 (suppl 136): 388-393.
16. Fish FJ: The influence of the tranquilizers on the Leonhard schizophrenic syndromes. Encéphale 1964;53:245-249.
17. Kelwala S, Ban TA: Is maintenance neuroleptic therapy necessary in shallow hebephrenia? J clin Psychiatry’ 1981:42:12,482.
18. Kelwala S, Ban TA: Febrile catatonia sustained by neuroleptics. Psychiatr J Univ Ottawa 1981;6: 135.
19. Ban TA: Psychopharmacology and psychiatric diagnosis, cyclic antidepressants and depression: New approaches. Clin Neuropharmacol 1984; 7 (suppl 1):S-222.
20. Leonhard K: Die dcfektschizophrenen Krank- heitsbildcr. Leipzig, Barth. 1936.
21. Astrup V, Fossum A, Holmboe R: Prognosis in Functional Psychoses. Springfield, Thomas, 1962.
22. Trostorff S: Verlauf und Psychose in der Ver- wandtheit bei den systematischen und den unsy- stematischen Schizophrenicn und die zykloiden Psychosen. Psychiatr Neurol Med Psychol 1975; 27:80-100.
23. Ungvari G: A contribution to the validity of Leonhard’s classification of endogenous psychoses. Acta Psychiatr Scand 1985;72:144-149.
24. Kukopulos A, Reginaldi D, Laddomada P, et al: Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatria 1980; 13:156-167.
25. Prien RF: Five-center study clarifies use of lithium, imipramine for recurrent affective disorders. Hosp Community Psychiatry 1984:35:1097-1098.
26. Prakash, R, Kelwala, S, Ban, TA: Neurotoxicity with combined administration of lithium and a neuroleptic. Compr Psychiatry 1982;23:567-571.
27. Mendels J, Ramsey A, Dyson WL, et al: Lithium as an antidepressant. Arch Gen Psychiatry 1979; 36:845-846.
28. Goodwin FK, Post RM: Catecholamine metabolite studies in the affective disorders: Issues of specificity and significance: in Usdin E, Ham- berger DA, Barchas JD (eds): Neuroregulation and Psychiatric Disorders. New York. Oxford University Press, 1977.
29. Murphy DL, Weiss R: Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. Am J Psychiatry 1972; 128: 1351-1357.
30. Ban TA: Composite Diagnostic Evaluation of Depressive Disorders (CODE-DD). Nashville. JM Productions, 1989.
31. Ragheb M, Ban TA: Amoxapine in psychotic- delusional depression. Am J Psychiatry 1984:141: 1312-1313.
32. Ban TA: Psychopharmacology. Baltimore, Williams & Wilkins. 1969.
33. Ban TA: CODE system: Theory and practice. Paper presented at International Symposium on Functional Psychoses Today. Trieste, June 17, 1989.
34. Perris C: The heuristic value of distinction between bipolar and unipolar affective disorders; in Angst J (ed): Classification and Prediction of Outcome of Depression. Stuttgart. Schattauer, 1974.
35. Ban TA: Chronic schizoprhenias: A guide to Leonhard’s classification. Compr Psychiatry 1982;23:155-165.
36. Petho, B, Ban TA: DCR Budapest Nashville in the Diagnosis and Classification of Functional Psychoses. Psychopathology 1988;21:153-239.